Dechra Pharmaceuticals plc (LON:DPH) will issue its quarterly earnings data before the market opens on Monday, September 4th.

Dechra Pharmaceuticals plc (LON DPH) opened at 1901.00 on Monday. The firm has a 50-day moving average price of GBX 1,770.38 and a 200-day moving average price of GBX 1,730.41. The firm’s market capitalization is GBX 1.76 billion. Dechra Pharmaceuticals plc has a one year low of GBX 1,225.00 and a one year high of GBX 1,970.00.

A number of equities analysts recently commented on the company. Stifel Nicolaus reaffirmed a “hold” rating and issued a GBX 1,550 ($20.12) target price on shares of Dechra Pharmaceuticals plc in a report on Tuesday, July 11th. Investec reaffirmed a “buy” rating and issued a GBX 1,840 ($23.89) target price on shares of Dechra Pharmaceuticals plc in a report on Thursday, July 6th. N+1 Singer reaffirmed a “buy” rating and issued a GBX 1,666 ($21.63) target price on shares of Dechra Pharmaceuticals plc in a report on Thursday, July 6th. Finally, Numis Securities Ltd reaffirmed an “add” rating and issued a GBX 1,890 ($24.54) target price on shares of Dechra Pharmaceuticals plc in a report on Thursday, July 6th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of GBX 1,648.71 ($21.40).

In other Dechra Pharmaceuticals plc news, insider Ian Page sold 134,500 shares of the stock in a transaction on Wednesday, June 21st. The stock was sold at an average price of GBX 1,927 ($25.02), for a total value of £2,591,815 ($3,364,682.59).

COPYRIGHT VIOLATION NOTICE: “Dechra Pharmaceuticals plc (DPH) Scheduled to Post Quarterly Earnings on Monday” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/28/dechra-pharmaceuticals-plc-dph-scheduled-to-post-quarterly-earnings-on-monday.html.

Dechra Pharmaceuticals plc Company Profile

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.

Receive News & Stock Ratings for Dechra Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals plc and related stocks with our FREE daily email newsletter.